EUnetHTA and EMA take stock of their cooperation

The European Network for Health Technology Assessment (EUnetHTA) and the European Medicines Agency (EMA) have published a Technical Report on their achievements since 2017.   The report covers the latest phase of an open and successful collaboration that began in 2010, and demonstrated that the synergies between regulatory evaluation and health technology assessment (HTA) along […]

PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.

This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA.  In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of bamlanivimab alone and bamlanivimab plus etesevimab combination for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for […]

OTCA25 Final Report and related documents now available

The final report for the Relative Effectiveness Assessment OTCA 25 “Stereotactic body radiation therapy (SBRT) for the treatment of lung, prostate and liver cancer”, is now available for access. The aim of this HTA was to assess if the use of SBRT is more effective and safer compared to radiotherapy (RT), surgery, or surgery and […]

OTCA27 – Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)- final report now available

The final report is now available for the Relative Effectiveness Assessment OTCA27 “Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH)”. The aim of this multi-technology HTA was to assess 21 minimally invasive surgical treatments for benign prostatic hyperplasia (BPH), either comparing minimally invasive treatments to each other or […]

EMA-EUnetHTA Bilateral Meeting held today.

The concluding EMA-EUnetHTA Bilateral Meeting under Joint Action 3 was held online today, marking a fitting conclusion to another stage of regular ongoing collaboration that stretches back through all three Joint Actions to the first bilateral meetings in 2010. Participants reviewed the joint achievements under the EMA/EUnetHTA workplan 2017-2021, showcasing the value of their collective […]

EMA-EUnetHTA Bilateral – December 2020 minutes now available

We are please to publish the minutes from the EMA-EUnetHTA Bilateral meeting, held 16 December 2020 online. Thanks to all attendees, and the continuing joint work undertaken by this collaboration. Access here: EMA-EUnetHTA Bilateral Meeting Minutes – Dec 2020 Further details on collaboration with the EMA, together with past meeting minutes, can be found here.

EUnetHTA Magazine – Winter 2021 – now available

We are please to finally publish another issue of the EUnetHTA Magazine, a collection of articles submitted by members and stakeholders that deal with HTA in Europe, EUnetHTA tasks and output, and, of course, COVID-19 and the network’s reprioritization this year towards it. We normally try to publish quarterly. However, 2020 has proven to be […]

EUnetHTA – Open Letter of Comment

This is an open letter, written by the Chair of the EUnetHTA Executive Board, Niklas Hedberg. It expresses commentary on the role of EUnetHTA within European HTA, and that of scientific journals. Please access the letter here: EUnetHTA – Open Letter of Comment For any questions regarding this, please contact the EUnetHTA Secretariat team at eunethta@zinl.nl

Minutes of EMA/EUnetHTA virtual meeting

We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetHTA. The meeting covered updates on EMA/EUnetHTA collaboration, JA3 final phase priorities, and 201-2021 Work Plan review, in addition to COVID-19 publication focus and other topics. Please access at this link: EMA-EUnetHTA July 2020 […]